Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026

Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license...

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Fineline Cube Aug 28, 2026

HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for...

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026

AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital...

Company Drug

Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

Fineline Cube Aug 28, 2026

Livzon Pharmaceutical (HKG: 1513) announced that lecankitug, jointly developed with Beijing Kanova Biopharma, has been...

Company Drug

TYK Medicines’ Asandeutertinib Wins NMPA Conditional Approval for EGFR-Mutant NSCLC with CNS Metastases

Fineline Cube Aug 28, 2026

TYK Medicines (HKG: 2410) announced that its independently developed next-generation EGFR-TKI, asandeutertinib (TY-9591), has received...

Company Drug

AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn’s Disease

Fineline Cube Aug 28, 2026

AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency...

Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026

TÜV Rheinland Greater China and United Imaging Healthcare Co., LTD have signed a strategic cooperation...

Company Deals

ImmuneOnco Doses First Patient in Phase 2 Trial of IMM2510 Combo for First-Line HCC

Fineline Cube Aug 28, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced that the first patient has been dosed in...

Company Medical Device

Asieris Wins EU CE Certification for APLD-2304, the World’s First Portable Single-Use Blue-Light Flexible Cystoscope

Fineline Cube Aug 28, 2026

Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its APLD-2304 flexible cystoscope has obtained...

Policy / Regulatory

China Health Report: NHC Data Shows Life Expectancy at 79.25 Years as Health Spending Reaches 6.7% of GDP

Fineline Cube Aug 28, 2026

The National Health Commission of China (NHC) released the Statistical Bulletin on Health Development in...

Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...

Company Drug PIC

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis

Fineline Cube Aug 28, 2026

Roivant (NASDAQ: ROIV) announced that the US Food and Drug Administration (FDA) has approved Lisraya...

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026

Hansoh Pharmaceutical Group (HKG: 3692) released its interim results for the first half of 2026,...

Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026

China‑based HitGen Inc. (SHA: 688222) released its interim report for the first half of 2026,...

Company Drug

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Fineline Cube Aug 27, 2026

CSPC Pharmaceutical Group (HKG: 1093) announced that SYS6090 (JMT108), a PD‑1/IL‑15 bispecific fusion protein, has...

Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Fineline Cube Aug 27, 2026

Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June...

Company Drug

Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status

Fineline Cube Aug 27, 2026

Huadong Medicine (SHE: 000963) announced that its investigational drug HDM2005 has been granted Fast Track...

Company Drug

Micot’s First‑in‑Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial

Fineline Cube Aug 27, 2026

Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of...

Policy / Regulatory

NMPA Suspends Sales and Use of Pierre Fabre’s Encorafenib Capsules Over Unapproved Manufacturing Change

Fineline Cube Aug 27, 2026

The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales...

Policy / Regulatory

China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)

Fineline Cube Aug 27, 2026

The National Healthcare Security Administration (NHSA) issued the Guiding Opinions on Improving the Payment Management...

Posts pagination

1 2 3 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.